Larazotide

Larazotide regulates tight junctions. Research examines its effects on the intestinal barrier and symptoms associated with celiac disease. It remains investigational and has no FDA approval.

Research settings generally indicate good tolerability. Adverse effects depend on the amount administered, route and individual response. Consult a clinician before considering use.

• Tissue Repair

  Most effective

  Research investigates faster wound closure and repair of damaged soft tissue.

• Gut Health

  Effective

  Investigations indicate potential benefits for the intestinal lining and gastrointestinal function.

  Human, randomised · 1 reference

• Joint Support

  Effective

  Potential joint benefits include less inflammation and better movement.

• Muscle Recovery

  Moderate

  Possible benefits include more rapid recovery from strained muscles and exertion.

These are commonly discussed research protocols — not medical advice. Consult a healthcare provider before use.

• TB-500 / BPC-157

  Compatible

• NSAIDs (Ibuprofen, Naproxen)

  Caution

• Corticosteroids

  Caution

• Anticoagulants

  Monitor

• GH Secretagogues

  Compatible

• NAD+

  Compatible

Diluent: Use bacteriostatic water; avoid saline because precipitation may occur.

1. Let the refrigerated vial stand at room temperature for 15–20 minutes before preparation.
2. Disinfect the stopper using an alcohol swab, then wait until it has dried fully in the air.
3. Measure the calculated quantity of bacteriostatic water with a sterile syringe. Use only this diluent; avoid saline because precipitation may occur.
4. Add the water gradually against the inner vial wall. Keep the stream away from the powder itself.
5. Rotate the vial with a gentle swirling motion. Do not shake forcefully, because this can degrade the contents.
6. Wait 2–3 minutes for the powder to dissolve completely, and check that the liquid is transparent and has no color.
7. Use an insulin syringe to withdraw the calculated amount for injection beneath the skin.
8. Inject in the thigh, abdomen or upper arm. Change the injection location each time to help prevent lipodystrophy.
9. Refrigerate the mixed solution at 2–8°C. Use it within a maximum of 28 days after preparation.

Week 1–2

Early anti-inflammatory activity may reduce pain and swelling in the affected tissue during weeks 1–2.

Week 2–4

During weeks 2–4, movement may improve as discomfort decreases and healing begins to accelerate.

Week 4–8

Weeks 4–8 may bring meaningful recovery milestones, more tissue repair and improved function.

Week 8–12

By weeks 8–12, healing may approach completion in many cases, with better strength and tissue integrity. These are research expectations rather than established outcomes for people.

• Nausea that is mild and more likely with larger doses
• Local redness or discomfort after injection
• Lightheadedness or dizziness · Rare
• Possible changes in blood pressure; monitor if you have hypertension

Larazotide: investigational in the US.

• US

  Investigational

  FDA: investigational; no approval for treatment. No 503A ban is identified; compounding authorization remains unknown. Telehealth is not applicable.

  Rx required

  No

  Telehealth

  N/A

1. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. (2015)

   PMID 25683116DOI 10.1053/j.gastro.2015.02.008

2. Coeliac disease and the intestinal barrier: mechanisms of disruption and strategies for restoration. (2026)

   PMID 40579122DOI 10.1136/gutjnl-2025-335373

3. The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate. (2016)

   PMID 26770266DOI 10.1177/1756283X15616576